Amgen, Inc. caused a stir at the European Society for Medical Oncology meeting in Madrid with promising data for its small-cell lung cancer offering tarlatamab but the reception for a late-stage study looking at a combination of its KRAS G12C inhibitor Lumakras and Vectibix for colorectal cancer was a bit cooler.
ESMO 23: Amgen's Lumakras/Vectibix Combo Clinches Colorectal Cancer Win
The higher dose of Amgen's Lumakras combined with Vectibix has demonstrated significant superiority in progression-free survival over investigator's choice of therapy in KRAS G12C-mutated metastatic colorectal cancer but the discussant at the combo's ESMO presentation wants to see overall survival data before getting too excited.
More from Anticancer
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.
• By
Servier takes a Phase I rationally designed cancer candidate for $70m up front, while Black Diamond will wait on more mature data for its Phase II lead candidate in lung cancer.
More from Therapy Areas
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.